Radcliffe Department of Medicine

Rethinking hypercortisolism screening in obesity and diabetes: A systematic review and meta-analysis.

Ferrari D. et al, (2026), Metabolism

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma.

Fuentes-Lacouture M-C. et al, (2026), FEBS J

Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery.

Mathara Diddhenipothage SAD. et al, (2026), Clin Endocrinol (Oxf)

RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Searle E. et al, (2026), Haematologica, 111

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.

Tsang C. et al, (2025), BMC Cancer, 25

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.

Perrot A. et al, (2025), Eur J Haematol, 114, 883 - 889

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.

Ramasamy K. et al, (2025), Clin Lymphoma Myeloma Leuk, 25, 337 - 348.e2

Correction to: Drug Insight: selective agonists and antagonists of the glucocorticoid receptor (Nature Clinical Practice Endocrinology & Metabolism, (2008), 4, 2, (91-101), 10.1038/ncpendmet0745)

McMaster A. and Ray DW., (2025), Nature Reviews Endocrinology

Impact of Female Sex and Mild Cortisol Secretion on Coagulation Profile in Adrenal Incidentalomas.

Bonaventura I. et al, (2024), J Endocr Soc, 9

Development of diagnostic algorithm for Cushing's syndrome: a tertiary centre experience.

Efthymiadis A. et al, (2024), J Endocrinol Invest, 47, 2449 - 2459

1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study.

Leavy OC. et al, (2024), ERJ Open Res, 10

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.

Lee HC. et al, (2024), Eur J Haematol, 113, 190 - 200

djusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.

Ramasamy K. et al, (2024), Haematologica, 109, 2585 - 2593

Predicting postoperative hypocortisolism in patients with non-aldosterone-producing adrenocortical adenoma: a retrospective single-centre study.

Bonaventura I. et al, (2024), J Endocrinol Invest, 47, 1751 - 1762

INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.

Leleu X. et al, (2024), Future Oncol, 20, 935 - 950

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.

Lehne M. et al, (2024), Eur J Haematol, 112, 701 - 713

Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.

Ludwig H. et al, (2024), Clin Lymphoma Myeloma Leuk, 24, e40 - e49.e3

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Mehta D. et al, (2023), Blood, 142, 6715 - 6715

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.

Richardson PG. et al, (2023), N Engl J Med, 389, 1009 - 1022

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL

Bahlis NJ. et al, (2023), HemaSphere, 7

Search results

Showing results for dexamethasone